In silico Design of a Multivalent Vaccine Against Candida albicans
Autor: | Sonia M. Rocha-Sanchez, Shikha Tarang, Michael D. Weston, Varun Kesherwani, Blake LaTendresse, Laramie Lindgren |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_treatment 030106 microbiology lcsh:Medicine Biology Epitope Article Peptide vaccines 03 medical and health sciences Antigen Candida albicans medicine Humans Protein analysis Computer Simulation lcsh:Science Multidisciplinary Immunogenicity lcsh:R Candidiasis Computational Biology Vaccine efficacy biology.organism_classification Virology Corpus albicans 030104 developmental biology Drug Design Vaccines Subunit Peptide vaccine Epitopes B-Lymphocyte lcsh:Q Fungal Vaccines Adjuvant |
Zdroj: | Scientific Reports, Vol 10, Iss 1, Pp 1-7 (2020) Scientific Reports |
ISSN: | 2045-2322 |
DOI: | 10.1038/s41598-020-57906-x |
Popis: | Invasive candidiasis (IC) is the most common nosocomial infection and a leading cause of mycoses-related deaths. High-systemic toxicity and emergence of antifungal-resistant species warrant the development of newer preventive approaches against IC. Here, we have adopted an immunotherapeutic peptide vaccine-based approach, to enhance the body’s immune response against invasive candida infections. Using computational tools, we screened the entire candida proteome (6030 proteins) and identified the most immunodominant HLA class I, HLA class II and B- cell epitopes. By further immunoinformatic analyses for enhanced vaccine efficacy, we selected the 18- most promising epitopes, which were joined together using molecular linkers to create a multivalent recombinant protein against Candida albicans (mvPC). To increase mvPC’s immunogenicity, we added a synthetic adjuvant (RS09) to the mvPC design. The selected mvPC epitopes are homologous against all currently available annotated reference sequences of 22 C. albicans strains, thus offering a higher coverage and greater protective response. A major advantage of the current vaccine approach is mvPC’s multivalent nature (recognizing multiple-epitopes), which is likely to provide enhanced protection against complex candida antigens. Here, we describe the computational analyses leading to mvPC design. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |